Video

Dr. Raje on the Utilization of bb21217 in Relapsed/ Refractory Multiple Myeloma

Noopur Raje, MD, discusses the utilization of bb21217 in patients with relapsed/refractory in multiple myeloma.

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, discusses the utilization of bb21217 in patients with relapsed/refractory in multiple myeloma.

In the phase 1 CRB-402 trial (NCT03274219), investigators studied the use of bb21217, a BCMA-targeted CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.

Updated findings from the trial showed that the overall response rate (ORR) was approximately 80%, and rates were similar among patients who received prior treatment with a PI3K inhibitor, Raje adds. At the highest dose of bb21217 of 450 × 106 CAR+ T cells explored during the dose-exploration trial, the ORR was more than 80%, Raje explains. 

Regarding toxicity, no new safety signals were seen, though central nervous system toxicity was observed at grades 1 and 2, Raje continues. These toxicity findings were similar to findings reported with the use of idecabtagene vicleucel (ide-cel; Abecma) and ciltacabtagene autoleucel (cilta-cel; Carvykti), Raje concludes. 

Related Videos
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD